 | |
| Clinical data | |
|---|---|
| Other names | 8-Methyltropinium bromide 2- propylvalerate |
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | 10 to 25% (oral) |
| Protein binding | Unknown |
| Metabolism | Hepatic |
| Eliminationhalf-life | Unknown |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.001.169 |
| Chemical and physical data | |
| Formula | C17H32BrNO2 |
| Molar mass | 362.352 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Octatropine methylbromide (INN) oranisotropine methylbromide (USAN), trade namesValpin,Endovalpin,Lytispasm and others,[1] is amuscarinic antagonist andantispasmodic. It was introduced to the U.S. market in 1963 as an adjunct in the treatment ofpeptic ulcer,[2] and promoted as being more specific to thegastrointestinal tract than other anticholinergics, although its selectivity was questioned in later studies.[3][4]
Octatropine has been superseded by more effective agents in the treatment of peptic ulcer disease, and is no longer used. It is still sold in some countries in combination with other drugs, such asphenobarbital andmetamizole.
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |